Literature DB >> 5064044

Clinical experience with mitomycin C in large infrequent doses.

T E Godfrey, D W Wilbur.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 5064044     DOI： 10.1002/1097-0142(197206)29:6<1647::aid-cncr2820290632>3.0.co;2-6

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  5 in total

1.  The haemotoxicity of mitomycin in a repeat dose study in the female CD-1 mouse.

Authors:  Gemma Molyneux; Frances M Gibson; Edward C Gordon-Smith; Andrew M Pilling; Kai Chiu Liu; Sian Rizzo; Susan Sulsh; John A Turton
Journal:  Int J Exp Pathol       Date:  2005-12       Impact factor: 1.925

2.  Mitomycin C: experience in the United States, with emphasis on gastric cancer.

Authors:  P S Schein; J S Macdonald; D Hoth; P V Wooley
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

3.  Pharmacokinetics of mitomycin C in non-oat cell carcinoma of the lung.

Authors:  R G Buice; H B Niell; P Sidhu; B J Gurley
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

4.  Potent effects of the monoclonal antibody-mitomycin C conjugate on human colon cancers.

Authors:  H Kotanagi; K Fukuda; N Ogata; M Takahashi; T Masuda; K Koyama; T Takahashi
Journal:  Jpn J Surg       Date:  1987-01

5.  Pharmacokinetics of mitomycin C in rabbit and human.

Authors:  G A van Hazel; J S Kovach
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.